WCLC 2025 - Posters & ePosters-P3.18.27 An Exploratory Clinical Study of TROP2 ADC SHR-A1921 Combined With Adebrelimab for Advanced NSCLC After Failure of First-line Standard Therapy

P3.18.27 An Exploratory Clinical Study of TROP2 ADC SHR-A1921 Combined With Adebrelimab for Advanced NSCLC After Failure of First-line Standard Therapy

Back to course

Pdf Summary

This phase II, single-center, single-arm exploratory clinical study (NCT06480136) investigates the efficacy and safety of TROP2 antibody-drug conjugate (ADC) SHR-A1921 combined with the PD-L1 inhibitor adebrelimab in patients with advanced non-small cell lung cancer (NSCLC) who have progressed after first-line standard therapy. The trial is investigator-initiated and sponsored by Jiangsu Hengrui Pharmaceuticals Co., Ltd.<br /><br />The primary objective is to evaluate the therapeutic efficacy of this combination in a patient population where treatment resistance typically leads to disease progression following initial therapy. Secondary objectives focus on assessing safety, while exploratory endpoints include analysis of blood and tumor tissue biomarkers to better understand response and resistance mechanisms.<br /><br />TROP2 is a transmembrane glycoprotein implicated in tumor progression and metastasis. Targeting TROP2 with ADCs offers a promising novel treatment strategy. Combining TROP2-ADC SHR-A1921 with PD-L1 blockade via adebrelimab aims to exploit potential synergistic effects, a combination currently underexplored as a second-line treatment for NSCLC.<br /><br />Enrollment for the trial started on August 6, 2024, and is ongoing. Patients receive the combination therapy every three weeks, with radiographic imaging assessments every six weeks initially and then every nine weeks after 54 weeks, continuing until disease progression, unacceptable toxicity, or withdrawal. Adverse events are monitored throughout and graded per CTCAE v5.0.<br /><br />This study is conducted at the Comprehensive Oncology Center, Shanghai Pulmonary Hospital, with clinical research input from Jiangsu Hengrui Pharmaceuticals. It seeks to address the unmet need for effective second-line treatments in advanced NSCLC by leveraging the novel combination of TROP2-directed ADC and immune checkpoint inhibition.

Asset Subtitle

Chunxia Su

Meta Tag

Speaker Chunxia Su

Topic Clinical Trials in Progress

Keywords

TROP2 antibody-drug conjugate

SHR-A1921

PD-L1 inhibitor

adebrelimab

non-small cell lung cancer

NSCLC

second-line therapy

clinical trial NCT06480136

Jiangsu Hengrui Pharmaceuticals

immune checkpoint inhibition